At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 19 enrolled
Drug / intervention
Volasertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia
In Brief
A Phase 1 clinical trial evaluating Volasertib for Leukemia, Myeloid, Acute. Completed, enrolled 19 participants across 6 sites.
Detailed Summary
To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedAug 2012
Primary CompletionMay 2015
TodayJul 2026
First PostedAug 10, 2012
Enrollment StartAug 1, 2012
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.9 years ago
Interventions
Volasertibdrug
Patient to receive volasertib